文献速递临床试验与 GCP

家庭无创通气联合氧疗与单纯氧疗对慢性阻塞性肺疾病急性加重后再次入院或死亡的影响:一项随机临床试验

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项随机临床试验纳入116例COPD急性加重后持续高碳酸血症(PaCO2>53 mmHg)患者,比较家庭氧疗联合家庭无创通气与单纯家庭氧疗。联合组12个月内再次入院或死亡的中位时间4.3个月,单纯氧疗组1.4个月,校正HR 0.49(95%CI 0.31-0.77;P=.002);12个月风险联合组63.4% vs 单纯氧疗组80.4%,绝对风险降低17.0%(95%CI 0.1%-34.0%)。

要点

  • COPD急性加重后持续高碳酸血症患者,家庭无创通气联合氧疗较单纯氧疗延长12个月内再次入院或死亡时间。
  • 联合组12个月再次入院或死亡风险63.4%,单纯氧疗组80.4%,绝对风险降低17.0%(95%CI 0.1%-34.0%)。
  • 12个月时联合组死亡16例,单纯氧疗组死亡19例。

核心结论

  • 在COPD急性加重后持续高碳酸血症患者中,家庭氧疗基础上加用家庭无创通气延长了12个月内再次入院或死亡的时间。

研究设计与样本

  • 随机临床试验,2010年至2015年从13个英国中心招募患者。
  • 纳入呼吸性酸中毒缓解后2周至4周持续高碳酸血症(PaCO2>53 mmHg)的患者,排除肥胖(BMI>35)、阻塞性睡眠呼吸暂停综合征或其他呼吸衰竭原因。
  • 筛查2021例,124例符合条件,最终116例随机:59例单纯家庭氧疗,57例家庭氧疗联合家庭无创通气。

主要发现

  • 联合组再次入院或死亡的中位时间4.3个月(IQR 1.3-13.8个月)vs 单纯氧疗组1.4个月(IQR 0.5-3.9个月),校正HR 0.49(95%CI 0.31-0.77;P=.002)。
  • 12个月再次入院或死亡风险联合组63.4% vs 单纯氧疗组80.4%,绝对风险降低17.0%(95%CI 0.1%-34.0%)。
  • 12个月时联合组死亡16例,单纯氧疗组死亡19例。
  • 完成12个月研究期的患者共64例(单纯氧疗组28例,联合组36例)。

关键数值与推荐

  • 单纯家庭氧疗组中位氧流量1.0 L/min(IQR 0.5-2.0 L/min)。
  • 家庭氧疗联合家庭无创通气组中位氧流量1.0 L/min(IQR 0.5-1.5 L/min)。
  • 家庭呼吸机中位参数:吸气正压24 cmH2O(IQR 22-26),呼气正压4 cmH2O(IQR 4-5),备用频率14次/分钟(IQR 14-16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death. OBJECTIVE: To investigate the effect of home NIV plus oxygen on time to readmission or death in patients with persistent hypercapnia after an acute COPD exacerbation. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of patients with persistent hypercapnia (Paco2 >53 mm Hg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible. INTERVENTIONS: There were 59 patients randomized to home oxygen alone (median oxygen flow rate, 1.0 L/min [interquartile range {IQR}, 0.5-2.0 L/min]) and 57 patients to home oxygen plus home NIV (median oxygen flow rate, 1.0 L/min [IQR, 0.5-1.5 L/min]). The median home ventilator settings were an inspiratory positive airway pressure of 24 (IQR, 22-26) cm H2O, an expiratory positive airway pressure of 4 (IQR, 4-5) cm H2O, and a backup rate of 14 (IQR, 14-16) breaths/minute. MAIN OUTCOMES AND MEASURES: Time to readmission or death within 12 months adjusted for the number of previous COPD admissions, previous use of long-term oxygen, age, and BMI. RESULTS: A total of 116 patients (mean [SD] age of 67 [10] years, 53% female, mean BMI of 21.6 [IQR, 18.2-26.1], mean [SD] forced expiratory volume in the first second of expiration of 0.6 L [0.2 L], and mean [SD] Paco2 while breathing room air of 59 [7] mm Hg) were randomized. Sixty-four patients (28 in home oxygen alone and 36 in home oxygen plus home NIV) completed the 12-month study period. The median time to readmission or death was 4.3 months (IQR, 1.3-13.8 months) in the home oxygen plus home NIV group vs 1.4 months (IQR, 0.5-3.9 months) in the home oxygen alone group, adjusted hazard ratio of 0.49 (95% CI, 0.31-0.77; P = .002). The 12-month risk of readmission or death was 63.4% in the home oxygen plus home NIV group vs 80.4% in the home oxygen alone group, absolute risk reduction of 17.0% (95% CI, 0.1%-34.0%). At 12 months, 16 patients had died in the home oxygen plus home NIV group vs 19 in the home oxygen alone group. CONCLUSIONS AND RELEVANCE: Among patients with persistent hypercapnia following an acute exacerbation of COPD, adding home noninvasive ventilation to home oxygen therapy prolonged the time to readmission or death within 12 months. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00990132.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Murphy PB, Rehal S, Arbane G, et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA. 2017. PMID: 28528348. doi:10.1001/jama.2017.4451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。